Council members include MI’s Raphael Hofstein and MI Board Chair Dr. Robert Bell
On November 20, the Government of Ontario launched the Ontario Health Innovation Council to support health innovation in Ontario. Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was named to the council.
By becoming a member of the Council, Hofstein will assist in identifying evidence-based opportunities in Ontario’s healthcare space and advancing them into practice on a global scale. (more…)
The Centre for Addiction and Mental Health and Assurex Health combine resources to bring personalized medicine in psychiatry, reducing the current trial-and-error approach
TORONTO – The Centre for Addiction and Mental Health (CAMH), Canada’s leading hospital for mental health, and Assurex Health, a global leader in personalized medicine, have signed an agreement for a joint venture to bring the benefits of this treatment approach to more Canadians.
The personalized approach helps to match the right medication at the right dose for each patient, based ...
President and CEO Dr. Raphael Hofstein speaks on healthcare innovation in Toronto
In an October 30 article, Yonge Street Media's Andrew Seale spoke with MI’s president and CEO Raphael Hofstein on the booming healthcare innovation coming from Toronto since 2005.
Seale's article is the first of a two-part series on technological innovation.
In the article, Hofstein credits the city’s intellectual infrastructure and access to healthcare resources for allowing innovation to flourish.
Three of MI’s start-up companies are also mentioned in the article.
Here’s an excerpt (links and ...
MI start-up ApneaDx Inc. among program's first round of participants
The first three companies selected to participate in the MaRS EXCITE program aim to improve outcomes for breast cancer, sleep apnea and drug-resistant hypertension.
The Excellence in Clinical Innovation and Technology Evaluation (EXCITE) initiative helps companies accelerate the adoption and reimbursement of innovative health technologies through a single, harmonized, pre-market, evidence-based process.
EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna Diagnostics Inc. as the program’s initial participants. (more…)
Program's second cohort includes eQOL, E-Twenty Development, Root2Crown, Treata Smart Solutions and TrendMD
TORONTO (May 14, 2013) — Five companies tackling pervasive healthcare challenges — such as assessing dental health, helping patients and medical personnel navigate hospitals with greater ease, staying current with medical literature, or creating digital tools to help care for the elderly or those with chronic health conditions — have been admitted to the University of Toronto Early Stage Technology (UTEST) program’s second cohort.
UTEST, supported by the University of ...
Bedside Clinical Systems featured on Research Innovation and Commercialization Centre (RICC) panel discussion
In an article for YourMississaugaBiz.com, Jon Cook writes, " 'The health-care industry is relying more on the private sector for innovation and small businesses need to make sure they have a strong value proposition in order to get their projects funded,' said Telus Health executive Nicholas Zamora."
The article describes a panel discussion organized by the Research Innovation and Commercialization Centre (RICC) on the "intersection of health care and technology ...
TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.
Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
“There’s growing consensus that transferring technologies from the university lab ...
A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada
CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.
Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ...
MI spin-off company one of 30 listed in North America and the United Kingdom
Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class.
Luke Timmerman's article, published December 3, 2012, sited Xagenic as one of only 30 "exciting biotech startups" to raise significant venture capital (at least $5 million) in the life sciences sector.
Xagenic, founded by Drs. Shana Kelley and Ted Sargent at the University of Toronto, was also the only Canadian company named to the list. (more…)